Company / Working Capital
Monte Rosa Therapeutics, Inc. Working Capital History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$220.5M
FY2024
5-year range
$14.3M / $332.0M
FY2020-FY2024
Trend
+16.3%
vs FY2023
Sector context
#163 of 213
Health Care
What the data says
Monte Rosa Therapeutics, Inc.'s working capital of $220M is lower than 77% of companies in the Health Care sector (FY2024). Working Capital returned to growth in FY2024 after 2 years of decline, reaching $220M.
Based on SEC 10-K filings.
$220M in FY2024 with a 3-year CAGR of -12.8%.
Declined from $250M to $220M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -12.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 213This company $220.5M Sector average $934.6M
▼
-76.4% below sector average
Key checks
Key Insights
- 3-year CAGR of -12.8%, indicating a declining trend.
- In FY2024, working capital increased 16.3% year-over-year.
- Ranks #163 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $220.5M | +16.3% |
| FY2023 | $189.6M | -24.2% |
| FY2022 | $250.3M | -24.6% |
| FY2021 | $332.0M | +2219.3% |
| FY2020 | $14.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026